ACP
GRTX

Acuta Capital Partners’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Acuta Capital Partners’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-262,500
Closed -$1.21M – 44
2021
Q4 		$1.21M Buy
+262,500
New +$868K 0.51% 34

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acuta Capital Partners's GRTX Position: Q1 2022 in Review

Acuta Capital Partners sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2022, closing a stake of 262,500 shares — an estimated $1.21M sold.

Acuta Capital Partners first reported a position in GRTX in Q4 2021 and held it in 1 quarter. The position peaked at $1.21M in Q4 2021. 47 funds tracked by Wall St. Rank hold GRTX as of Q1 2022.

  • Acuta Capital Partners reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 262,500 Galera Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.21M.
  • Acuta Capital Partners first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Acuta Capital Partners's Galera Therapeutics, Inc. Common Stock position peaked at $1.21M in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Acuta Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.